Given that false positive values represent a major concern for a diagnostic biomarker, and that plasma levels of LAMC2 in patients with cystadenoma—as well as PTX3 levels in patients with chronic pancreatitis—were still significantly lower than in PDAC patients, we propose that intermediate levels of LAMC2 and PTX3 (higher than in healthy donors, but lower than in PDAC patients) may identify patients for which further diagnostic imaging is warranted. This evidence concerns the gene PTX3 and cystadenoma.